Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside.
The company was expected to report a third-quarter loss and plummeting sales. 
Via Investor's Business Daily
This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said DocuSign, Inc. 
Via Benzinga
CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross’ Tongue
Bill Gross, the Bond King, is wading into the world of equity arbitrage with these three stocks - but are they worth the risk for investors? 
Via InvestorPlace
Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years
 
Via Benzinga
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Seagen Inc.
Via Business Wire
This High-Yield Dividend Stock Is a Proven Wealth Creator
This heavily sold-off pharma stock is a bargain. 
Via The Motley Fool
Looking At Seagen's Recent Unusual Options Activity
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
From Seagen Inc.
Via Business Wire
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
From Seagen Inc.
Via Business Wire
The 7 Most Undervalued Long-Term Stocks to Buy: October 2023
Equities remain under pressure, but if you’re looking to be a contrarian investor, it’s a good time to look for undervalued long-term stocks. 
Via InvestorPlace
(SGEN) - Analyzing Seagen's Short Interest
 
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High
Via Investor Brand Network
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
Earnings Outlook For Seagen
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
The companies studied a combination of Keytruda and Padcev in bladder cancer patients. 
Via Investor's Business Daily
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
From Seagen Inc.
Via Business Wire
Here's How Much $1000 Invested In Seagen 5 Years Ago Would Be Worth Today
 
Via Benzinga
How Is The Market Feeling About Seagen?
 
Via Benzinga
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
From Seagen Inc.
Via Business Wire
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END 
Via FinancialNewsMedia
Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023
From Seagen Inc.
Via Business Wire
Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023
From Seagen Inc.
Via Business Wire
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END 
Via FinancialNewsMedia
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant... 
Via Benzinga
2 High-Yield Dividend Stocks to Buy in October
These two high-yield dividend stocks are too cheap to ignore. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.